Skip to main
AXSM

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

Axsome Therapeutics (AXSM) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 44%
Buy 50%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Axsome Therapeutics is well-positioned for success with their diverse pipeline, including Solriamfetol for multiple indications and other candidates in clinical development. The company has a recent successful drug launch and has seen strong revenue growth. Positive results in Phase 3 trials for ADHD in adults and plans for treating excessive daytime sleepiness show promising potential for future growth and success.

Bears say

Axsome Therapeutics is currently facing significant risks in achieving their projected valuation. The company has a high discount rate of 12% applied to future cash flows, and potential setbacks in clinical trials could hinder the success of their pipeline products. While their current drug, SUNOSI, has demonstrated growth in sales, its market share is expected to decline over time due to increased competition. Additionally, the company faces risks related to R&D, regulatory hurdles, and competition in the CNS market.

Axsome Therapeutics (AXSM) has been analyzed by 16 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 50% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Axsome Therapeutics (AXSM) Forecast

Analysts have given Axsome Therapeutics (AXSM) a Buy based on their latest research and market trends.

According to 16 analysts, Axsome Therapeutics (AXSM) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $261.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $261.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Axsome Therapeutics (AXSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.